Gerardo Hernandez - 02 Mar 2026 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role: Chief Financial Officer
Signature: By: /s/ Gerardo Hernandez
Issuer symbol: TMDX
Transactions as of: 02 Mar 2026
Net transactions value: -$1,117,382
Form type: 4
Filing time: 04 Mar 2026, 21:40:27 UTC
Previous filing: 05 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hernandez Gerardo	Chief Financial Officer	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER	By: /s/ Gerardo Hernandez	04 Mar 2026	0002046180

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TMDX	Common Stock	Sale	$52,170	-375	-2.5%	$139.12	14,689	02 Mar 2026	Direct	F1
transaction	TMDX	Common Stock	Options Exercise		+1,324	+9%	$77.12^*	16,013	04 Mar 2026	Direct
transaction	TMDX	Common Stock	Sale	$194,906	-1,324	-8.3%	$147.21	14,689	04 Mar 2026	Direct	F2
transaction	TMDX	Common Stock	Options Exercise		+5,912	+40%	$69.84^*	20,601	04 Mar 2026	Direct
transaction	TMDX	Common Stock	Sale	$870,306	-5,912	-29%	$147.21	14,689	04 Mar 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TMDX	Stock Option (Right to Buy)	Options Exercise		-1,324	-25%	$0.000000^*	3,975	04 Mar 2026	Common Stock	1,324	$77.12	Direct	F3
transaction	TMDX	Stock Option (Right to Buy)	Options Exercise		-5,912	-31%	$0.000000^*	13,010	04 Mar 2026	Common Stock	5,912	$69.84	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $147.14 to $147.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3	The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 24, 2025 until the option is fully vested on February 24, 2029, subject to continued service.
F4	The option vested as to 25% of the shares underlying the option on December 2, 2025 and will continue to vest as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.